Seoul National University · 医学
Professor Jung-Joon Sung's research lab specializes in neuroimmunology and neurodegenerative diseases, with a primary focus on motor neuron disorders such as amyotrophic lateral sclerosis (ALS) and inflammatory demyelinating polyneuropathies like Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP). The lab investigates the pathophysiology of these conditions using advanced electrophysiological and imaging techniques, with particular emphasis on identifying early prognostic biomarkers and optimizing treatment timing. Recent work includes deep learning-based radiological phenotyping and quantitative vocal analysis to detect subclinical disease progression.
Figures are computed from collected data and may differ slightly.
Our study highlights the timing of IVIg as a modifiable prognostic factor in GBS. The earlier IVIg is initiated, the better the outcomes, with the ideal time window being within the first 2 weeks. These findings underscore the importance of prompt diagnosis and early intervention to optimize recovery in GBS patients.
Early treatment initiation is a key modifiable determinant of favorable long-term disability in CIDP. These findings underscore the importance of timely diagnosis and prompt treatment to prevent irreversible axonal damage.
Neuroinflammation does not appear to be a primary contributor to the pathogenesis of SBMA. Serum Spp1 levels may serve as a reliable biomarker for disease progression and prognosis in ALS. These findings expand our understanding of these two distinct motor neuron disorders and offer a potential biomarker for future studies.
The available quantitative methods for evaluating bulbar dysfunction in patients with amyotrophic lateral sclerosis (ALS) are limited. We aimed to characterize vowel properties in Korean ALS patients, investigate associations between vowel parameters and clinical features of ALS, and analyze subclinical articulatory changes of vowel parameters in those with perceptually normal voices. Forty-three patients with ALS (27 with dysarthria and 16 without dysarthria) and 20 healthy controls were prospe
Open papers in the app to read, cite, and organize with AI.
